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Haemonchus contortus is a parasitic nematode that infects the abomasum of 
ruminants. While several classes of anthelmintic drugs exist to control nematode infections, 
H. contortus is resistant to all of them. Therefore, novel drug targets such as ligand-gated 
chloride channels (LGCCs) need to be characterized. The objective of this thesis was to 
further characterize the agonist binding pocket in Hco-UNC-49BC, the LGCC gated by γ-
aminobutyric acid (GABA) within H. contortus. To meet this objective, each amino acid 
residue in binding loop E was changed to a cysteine and analyzed via electrophysiology 
and the substituted cysteine accessibility method. It was found that of the 18 loop E mutants 
analyzed, His142, Ser144, Arg147, and Ser157, all played a role in channel activation and were 
sensitive to modification by a methanethiosulfonate reagent. In addition, mutants lacking 
His142 showed increased sensitivity to a variety of agonists and produced maximal chloride 
conductance to the previously characterized partial agonist 5-aminovaleric acid.  Overall, 
this thesis has revealed potential differences in the agonist binding pocket between 
nematode UNC-49 and mammalian GABA receptors that could be exploited in the design 
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1.1 Haemonchus contortus 
Haemonchus contortus is a parasitic nematode classified within the same phylum 
(Nematoda) and clade (V) as the free living model organism Caenorhabditis elegans 
(Blaxter et al., 1998). H. contortus consists of morphologically distinct males and females, 
and reproduces rapidly (Waller & Chandrawathani, 2005). Notorious for infecting the 
abomasum of ruminating animals such as cattle, sheep, and goats, female H. contortus 
nematodes can produce up to 10,000 eggs per day (Veglia, 1915).  The eggs laid in the 
fourth stomach chamber of the ruminant get passed through the mammal’s gastrointestinal 
system, and are eventually discarded through the feces (Veglia, 1915). Once in the 
environment two main phases, free-living and parasitic, punctuate the life cycle of H. 
contortus (Nikolaou & Gasser, 2006). H. contortus remains free-living until taken up by a 
host orally, whereby the parasitic life style is adopted upon binding of the nematode to the 
mucosa layer of the abomasum (Idris et al., 2011).  
 These gastrointestinal parasites flourish in the host’s stomach chamber by 
extracting and subsequently feeding on blood.  By altering the abomasal environment of 
its host, through the reduction of acid (Simpson, 2000) and disruption of the mucosa 
(Salman & Duncan, 1984), H. contortus may thrive in this environment for an extended 
period of time, producing the chronic infection haemonchosis (Idris et al., 2011; Waller & 
Chandrawathani, 2005). Infection from H. contortus can ultimately lead to reduced growth, 
weight loss, severe anemia, and death (Schallig, 2000; Idris et al., 2011).  
Referred to as one of the leading causes of morbidity in livestock (Waller et al., 
1996; Komuniecki et al., 2012), H. contortus infections are a problem all over the world 
(Prichard, 2001; Waller & Chandrawathani, 2005). Livestock farming suffers great 
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financial strain as produce is lost to infection, and treatment options cost millions of dollars 
globally (Waller & Chandrawathani, 2005). As such, H. contortus is considered to be one 
of the most economically significant livestock parasites, bringing the threat of 
gastrointestinal nematode infections to the fore front of global concern (Waller & 
Chandrawathani, 2005).  
 
1.2 Anthelmintic Drugs and Resistance 
 There are three main classes of broad spectrum anthelmintics used for the treatment 
of parasitic infections, including those caused by H. contortus; these drug classes include 
benzimidazoles, macrocyclic lactones, and imidazolthiazoles (Martin et al., 1997; Ghisi et 
al., 2007; Williamson et al., 2011). Each of the three drug classes exhibits a unique mode 
of action, targeting different aspects of the parasite to eliminate the infection. Specifically, 
benzimidazoles target structural components (β-tubulin) of the cell, while 
imidazolthiazoles and macrocyclic lactones function by acting as agonists for key receptors 
in signalling pathways found within the parasite nervous system.   
Benzimidazoles, such as thiabendazole, were the first class of anthelmintics 
introduced to the market in 1963 (Brown et al., 1961; Robinson et al., 1965). Compounds 
within this drug class exert their effect by specifically binding to the parasite’s β-tubulin 
with high affinity (Martin et al., 1997; Blackhall et al., 2008). Once bound, the drug 
prevents the polymerization of β-tubulin, an important molecule required for the formation 




Macrocyclic lactones (commonly called avermectins) such as ivermectin, 
doramectin, and moxidectin, act on anion channels (Martin et al., 1998). Specifically, 
avermectins are known to agonize and selectively activate invertebrate glutamate-gated 
chloride channels (GluCl) irreversibly (Martin et al., 1997; Jagannathan et al., 1999; 
Cheeseman et al., 2001; Yates et al., 2003; McCavera et al., 2009). GluCl receptors, only 
found in invertebrates (Martin et al., 1997), are similar to other ligand-gated ion channels 
in structure; the subunits for which have been isolated and characterized within H. 
contortus (Forrester et al., 1999, 2002). Showing a high affinity for binding both ivermectin 
and moxidectin, continuously activated GluCl receptors are thought to inhibit pharyngeal 
pumping, likely eliminating the parasite by preventing its ability to feed (Geary et al., 1993; 
Laughton et al., 1997; Forrester et al., 1999, 2002; Yates et al., 2003; McCavera et al., 
2009).      
Finally, imidazolthiazoles (also referred to as cholinergic agonists) such as 
pyrantel, levamisole, and morantel, agonize and selectively activate acetylcholine-gated 
cation channels found within the somatic muscle of H. contortus (Martin et al., 1997, 1998, 
Neveu et al., 2007). The constantly activated acetylcholine-gated cation channels causes 
muscle paralysis, allowing the host to eliminate the parasite naturally (Martin et al., 1998).  
 Extensive use of the aforementioned drugs has resulted in a wide-spread 
observation of anthelmintic resistance amongst nematodes (Martin et al., 1998; Waller & 
Chandrawathani, 2005; Williamson et al., 2011). H. contortus is prominently cited in drug 
resistance reports (Waller & Chandrawathani, 2005), and numerous studies have attempted 
to elucidate the nematode’s ability to become resistant to multiple drug classes (Kwa et al., 
1995; Sangster et al., 2005; Ghisi et al., 2007; Neveu et al., 2007; Blackhall et al., 2008; 
5 
 
McCavera et al., 2009, Williamson et al., 2011). With respect to benzimidazoles, various 
point mutations in β-tubulin subunits, such as phenylalanine-200 to tyrosine, has been 
marked as the main cause of resistance to drugs in this class (Kwa et al., 1995; Ghisi et al., 
2007; Blackhall et al., 2008). In this sense, altering the target of the drug is believed to be 
sufficient to confer the resistance observed. However, there is some indication that higher 
allele frequencies of P-glycoprotein, a membrane protein capable of transporting drugs out 
of the cell, may contribute to benzimidazole resistance (Blackhall et al., 2008).   
 Similar to benzimidazole resistance, various point mutations in GluCl subunits and 
nicotinic acetylcholine-gated ion channels, were found to be mainly responsible for the 
resistance to avermectins and imidazolthiazoles respectively (Sangster et al., 2005; Neveu 
et al., 2007; McCavera et al., 2009). In addition, resistance to the cholinergic agonist 
levamisole was associated with a down regulation in the number of susceptible receptors 
expressed, as well as a lack of incorporation of subunits sensitive to the drug (Sangster et 
al., 2005).  
It is clear from the literature that the growing resistance observed in H. contortus is 
becoming a serious concern. Wide spread evolutionary changes occurring in specific drug 
targets in the parasite have sparked the need for a deeper understanding of nematode 







1.3 Ligand-gated Ion Channels 
 Ligand-gated ion channels (LGIC) mediate fast chemical neurotransmission once 
opened by a substrate specific agonist such as a neurotransmitter (Unwin, 1993). Found 
throughout the nervous system of vertebrates and invertebrates, LGIC control excitatory 
and inhibitory responses depending upon the channel’s permeability to anions (inhibitory) 
or cations (excitatory). As these channels are involved in the neurotransmission responsible 
for locomotion and muscle contraction, they are key targets for anti-parasitic drugs and 
have become the basis for current research (Komuniecki et al., 2012).    
 Of particular interest is the Cys-loop superfamily of LGICs.  Many of the cys-loop 
receptors are anion-permeable ligand-gated chloride channels (LGCCs), responsible for 
rapid inhibitory synaptic transmission (Sine & Engel, 2006). LGCCs and other Cys-loop 
receptors are pentameric membrane proteins, composed of subunits with extracellular (N 
terminal ligand-binding domain and the C-terminus), intracellular, and transmembrane 
(M1, M2, M3, M4) domains (Chebib & Johnston, 2000; Jansen et al., 2008; Collingridge 
et al., 2009) (Figure 1).  The central ion pore of LGCCs, through which chloride ions 
permeate after channel activation, is formed from the transmembrane segment, M2 (Jansen 
et al., 2008). The characteristic binding loops (A-F) of the receptor are located 








                        
 
Figure 1. Cys-loop family ligand-gated ion channel structure. A) Schematic of pentameric structure in which 
subunits arrange to create a pore gated by agonist binding. B) Representative structure of one subunit of a 
LGIC showing 4 transmembrane regions (M1-M4), intracellular loops, and extracellular loops complete with 
a disulphide bond connecting two cysteine residues (Adapted from Raymond & Satelle, 2002).    
 
 
 There are many families of LGCCs, in both vertebrates and invertebrates, classified 
based on the neurotransmitter responsible for opening the channel. However, there are 
many unique classes of LGCC found in Caenorhabditis elegans and H. contortus, not 
found within mammals. This principal alone makes them ideal drug targets for new anti-
parasitic pharmaceuticals, as they have the potential to eliminate the parasite without 
harming the host.  These novel nematode LGCCs can be activated by neurotransmitters 
such as GABA (Siddiqui et al., 2010), glutamate (Cully et al., 1994; Dent, 1997), 
acetylcholine (Putrenko et al., 2005), and more recently acknowledged biogenic amines, 
serotonin, dopamine, and tyramine (Rao et al., 2010). The thesis herein focuses on the 








1.4 GABA-gated Receptors 
Classified as an LGCC, ionotropic GABA receptors share a similar structure with 
other Cys-loop receptors, and are important for mediating rapid inhibitory 
neurotransmission in both vertebrates and invertebrates (Cockcroft et al., 1990, 
Collingridge et al., 2009; Siddiqui et al., 2010). In the vertebrate nervous system, two 
classes of ionotropic GABA receptors (GABAA and GABAC) are prominently distributed 
throughout. The agonist binding pocket of GABA receptors is formed from the interactions 
of six discontinuous extracellular binding loops (Accardi & Forrester, 2011).  Labelled 
loops A-F, these binding regions bridge to form an interaction between the principle (loops 
A-D) and adjacent (loops E-F) subunits (Accardi & Forrester, 2011) (Figure 2).  
 
 
Figure 2. Model of two adjacent Hco-UNC-49B subunits. Binding loops are indicated (A-F) as they interact 
with a docked GABA molecule (Adapted from Accardi & Forrester, 2011).  
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These binding loops are present in all of the familial GABA receptors, and have 
been observed in homology models using the acetylcholine binding protein (AChBP) as a 
template (Bamber et al., 2003). The presence of the binding loops in multiple GABA 
receptors may indicate an important conservative feature among them, although there are 
varying pharmacological profiles of GABA receptors suggesting slight variances that need 
to be explored.  
 As mentioned previously, GABAA and GABAC are two classes of ionotropic 
GABA receptors found in the vertebrate nervous system.  Within humans, GABAA 
receptors serve as drug targets to alleviate insomnia, epilepsy, and anxiety (Sieghart, 1995).  
The vertebrate genome encodes multiple subunits that assemble in a heteromeric fashion 
to form GABAA receptors with varying roles and functions. While the number of subunits 
and potential pentameric combinations seem endless, subunit expression and strict 
assembly limit the number of GABAA receptor subtypes to about a dozen experimentally 
observed (Bamber et al., 2003; Miller & Aricescu, 2014). For example, the human GABAA 
receptor subunits include α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3, and while it appears that multiple 
subtypes can be formed from such a large pool of subunits, the number of physiologically 
functional channels that form is limited, generally resulting in a configuration of two α, 
two β, and one γ subunit (Miller & Aricescu, 2014). It should also be noted that GABAA 
receptors can assemble into functional homomeric channels, but are not found in discrete 
populations within the brain (Miller & Aricescu, 2014). Furthermore, the homomeric 
version of GABAA receptors have been useful for modelling heteromeric channels, as 
evidenced by the recent elucidation of crystal structure of the human β3 homopentamer 
GABA receptor (Miller & Aricescu, 2014).  
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 GABAC receptors are another class of GABA receptors found within the vertebrate 
nervous system. These receptors resemble GABAA receptors, but are classified separately 
due to their distinct pharmacology and minor variance in structure (Chebib & Johnston., 
2000; Sedelnikova et al., 2005).  Unlike GABAA receptors, GABAC receptors are slightly 
simpler in structure, only configured into a homomeric receptor with five identical subunits 
(Chebib & Johnston, 2000). Pharmacologically, GABAC receptors are uniquely insensitive 
to bicuculline and can be selectively antagonized by 1,2,5,6-tetrahydropyridine-4-yl-
methylphosphinic acid (Sedelnikova et al., 2005). These distinct antagonist profiles 
indicate that, while structurally similar to GABAA receptors, these two classes have 
different agonist/antagonist binding pockets (Sedelnikova et al., 2005).  
 
1.5 UNC-49 in C. elegans (Cel-UNC-49) 
 GABA is an important neurotransmitter in the nervous system of vertebrates as 
wells as invertebrates; as such, inotropic GABA-gated receptors can be found in both. In 
invertebrates, GABA receptors are primarily the targets of pesticides and anti-parasitic 
compounds (Bamber et al., 2003). Within the free-living model organism C. elegans, the 
gene unc-49 encodes for a GABA receptor (Cel-UNC-49) responsible for mediating 
requisite body muscle inhibition during nematode locomotion (Bamber et al., 2003). The 
unc-49 gene has been identified in many free-living and parasitic nematodes (including H. 
contortus), suggesting its importance to GABAergic systems in nematodes (Accardi et al., 
2012).   
 Similar to vertebrate GABA receptors, Cel-UNC-49 is a pentameric receptor 
composed of five subunits. However, unlike the expansive choices of subunits available in 
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the vertebrate genome, Cel-UNC-49 can only be composed of three possible subunits.  The 
three subunits, UNC-49A, UNC-49B, and UNC-49C, are created through alternative 
splicing of the unc-49 gene (Bamber et al., 1999). Through this process, each subunit 
maintains the same N-terminal ligand-binding domain, but contains a unique C-terminal 
domain obtained from unique splicing (Bamber et al., 1999). Interestingly, 
pharmacological analysis indicated that subunits UNC-49C and UNC-49B can assemble 
to form a heteromeric receptor, while UNC-49B can assemble to form a homomeric 
receptor (Bamber et al., 2003).  Upon further analysis of these receptors, it was determined 
that the homomeric receptor (Cel-UNC-49B) is more sensitive to GABA than the 
heteromeric channel (Cel-UNC-49B/C), indicating functional differences between the two 
subtypes (Bamber et al., 2003). 
 Differences between Cel-UNC-49 receptors and mammalian GABAA receptors 
were also ascertained by pharmacological analysis. Through experimentation, it was found 
that unlike vertebrate GABAA receptors, Cel-UNC-49 receptors are relatively insensitive 
to bicuculline inhibition or benzodiazepine enhancement (Bamber et al., 2003).  In order 
to find structural causation for the differences observed, Bamber et al. (2003) compared 
the sequences of the UNC-49 (UNC-49B, UNC-49C) and GABAA (α, β, γ) subunits.  It 
was discovered that the C. elegans UNC-49 subunits are not orthologous to the GABAA 
subunits, but rather closely resemble the GABA-gated RDL receptors found in insects such 
as Drosophila melanogaster (Bamber et al., 2003).  Despite this, GABAA receptor subunits 
and UNC-49 subunits do share similarity in several key structural components (Bamber et 
al., 2003).  Therefore, although UNC-49 receptors are more similar to GABA receptors in 
other invertebrates, they still share a functional and structural overlap with vertebrate 
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GABAA receptors (Bamber et al., 2003). This can be described as a conservation of the 
GABA receptor family, and knowledge gained from the study of one specific GABA 
receptor may be applicable, in some way, to all of them.    
 
1.6 UNC-49 in H. contortus (Hco-UNC-49) 
 UNC-49 in H. contortus (Hco-UNC-49) is a GABA-gated chloride channel that has 
a high degree of sequence similarity, and is orthologous, to UNC-49 in C. elegans (Accardi 
et al., 2012). In addition, Hco-UNC-49 can form heteromeric (assembly of Hco-UNC-49B 
and Hco-UNC-49C subunits) or homomeric (Hco-UNC-49B only) channels (Siddiqui et 
al., 2010). While these receptors resemble the assemblage observed in C. elegans, the 
pharmacological implications of the combinatorial subunits differ. In the previous section 
of the thesis, it was stated that Cel-UNC-49B was more sensitive to GABA than Cel-UNC-
49B/C (Bamber et al., 2003).  In the case of H. contortus, the opposite is known to be true 
(Siddiqui et al., 2010). Further study employing cross-species-assembled receptors, those 
containing both C. elegans and H. contortus subunits, determined that the Hco-UNC-49B 
subunit was responsible for the alterations in agonist sensitivity (Siddiqui et al., 2010). 
These observations suggest that there are functional differences between the two nematode 
GABA receptors, probably attributed to underlying structural differences.    
 To begin to elucidate the unique pharmacological profile produced by the Hco-
UNC-49 receptor, mutagenesis experiments were conducted (Accardi & Forrester, 2011). 
Site-directed mutagenesis was performed to determine which residues in loops A-D are 
required for GABA activation of the Hco-UNC-49 channel. It was found that most of the 
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residues that are known to play a role in the activation of mammalian GABA receptors, 
also appear to play a role in Hco-UNC-49. While this study provided some important 
information of the structure of the nematode GABA receptor, and uncovered important 
structural links between the binding loops in invertebrates and vertebrates, further studies 
on the role of amino acid residues in the additional loops E and F, would provide a more 
complete picture. One such method that could provide a detailed understanding of which 
residues are involved in agonist binding within the UNC-49 receptor, is a type of 
mutational technique called the substituted cysteine accessibility method (SCAM).  
 
1.7 Substituted Cysteine Accessibility Method 
 Traditionally, the role amino acid residues play in the binding and activation of a 
receptor was determined through the use of site-directed mutagenesis. If the sensitivity of 
the receptor to its ligand altered when a particular amino acid was mutated, it could be 
assumed that the residue in question was necessary for the receptor’s function. While this 
approach is still used to this day to indicate which residues are required for function, it does 
not indicate whether the residue is interacting with the ligand directly (i.e. lining the 
binding pocket) or indirectly (i.e. needed for structure or allosteric modulation).   
 Designed to overcome this limitation, Karlin & Akabas (1998) developed the 
substituted cysteine accessibility method (SCAM). In this analytical technique, the 
structure and function of the binding site in a receptor is probed through the combination 
of mutagenesis and chemical modifications. Within this procedure, mutants containing a 
cysteine residue, in lieu of the residue of interest in the wild-type receptor, are subjected to 
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applications of thiol specific reagents (methanethiosulfonate derivatives). If the cysteine 
being analyzed is in an open aqueous environment typical of the agonist binding pocket, 
the cysteine will be available for modification. The methanethiosulfonate (MTS) reagent 
will react with the exposed residue, irreversibly modifying and attaching to the cysteine 


















Figure 3. Modification of the sulfhydryl group on a cysteine residue by a methanethiosulfonate (MTS) 
reagent (A). Structures of two MTS reagents showing side groups (displayed as X in (A)), MTSET and 
MTSEA (B). (Adapted from Newell & Czajkowski, 2007) 









In theory, this modification will block the binding site, thereby altering the function of the 
receptor, and the sensitivity to the applied agonist. The effect of MTS modification is 
determined through functional analysis using two electrode voltage clamp 
electrophysiology on Xenopus laevis oocytes expressing the receptor of interest (Newell & 
Czajkowski, 2007).  
 When probing the binding site of a receptor, looking for residues that may directly 
interact with the agonist, two types of experiments are generally performed. The first is a 
cysteine accessibility test, used to determine if the introduced cysteine is in an aqueous 
environment. Applying agonist before and after the application of an MTS reagent, the 
currents elicited are compared (see Newell & Czajkowski, 2007 for more detail). If the 
amount of activation decreases after MTS application, it can be concluded that the cysteine 
being analyzed was in an aqueous environment, and accessible for modification by MTS. 
If the response after MTS application is virtually unchanged, the cysteine residue being 
examined is most likely imbedded in the receptor, and located in a hydrophobic region of 
the protein (Newell & Czajkowski, 2007).  
 While the above technique can be used to determine if a cysteine residue is in an 
aqueous environment, it cannot determine if this environment is in the binding pocket of 
the receptor, or if it lies in another aqueous region. Protection assays are used to overcome 
this limitation. In this technique, low concentrations of the irreversibly reactive MTS 
reagent is co-applied with a high concentration of agonist.  Similar to the cysteine 
accessibility test, the agonist is applied to the oocyte before and after co-application to 
determine effects. Since the agonist is of high concentration (EC90-EC100), especially 
compared to the MTS reagent, it should outcompete MTS for binding in the binding pocket. 
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If the cysteine residue under analysis lies in the pocket, then the agonist should protect the 
residue from modification (Newell & Czajkowski, 2007). This protection should allow 
subsequently applied agonist to activate the receptor at a normal level (Figure 4).  If 
however the cysteine lies outside the binding pocket, the agonist will not be able to block 
MTS, and therefore full modification of the cysteine by MTS will occur.   
 
 
Figure 4. Schematic representation of agonist (gray sphere) protection from the modification of an MTS 
reagent (CH3SO2SCH2CH2X). Binding pocket, sulfhydryl group, MTS, and agonist not to scale (Adapted 
from Newell & Czajkowski, 2007). 
 
It should be noted that a cysteine protected by the co-application of agonist may 
not necessarily be lining the pocket. When an agonist binds, allosteric changes to the 
conformation of the receptor occurs. In this sense, a cysteine protected by the agonist may 
either line the binding pocket (i.e. direct protection), or may be hidden from the MTS upon 
conformational changes (i.e. indirect protection). In such cases, protection assays can be 
carried out using a competitive antagonist. Covering the same binding pocket as the 
agonist, but without allosteric modulation upon binding, a competitive antagonist will only 




1.8 Objectives and Thesis Rationale 
 According to the aforementioned literature, drug resistance to multiple drug classes 
displayed by H. contortus is a globally expanding problem. Generating a growing need for 
the identification of novel drug targets, this issue has created an opportunity to garner a 
deeper understanding of the invertebrate nervous system. As such, more knowledge must 
be gained about LGIC, the LGCCs, and the structural differences that may account for 
pharmacological variances observed between vertebrate and invertebrate receptors 
belonging to the same family. 
     Expanding on this idea, the following thesis will focus on further characterizing the 
amino acid residues of Hco-UNC-49, exploring another binding loop not examined before 
in H. contortus.  Loop E is a region of the receptor that has been shown to play an important 
role in agonist binding in other GABA receptors (Sedelnikova et al., 2005; Kloda & 
Czajkowski, 2007). Furthermore, many of the residues composing loop E have been found 
to line the agonist binding pocket of vertebrate GABA receptors, and may directly interact 
with GABA.  In 2005, Sedelnikova et al. used a combination of mutagenesis and SCAM 
to locate pocket lining residues situated in loop E of the vertebrate GABAc receptor subunit 
ρ1. Using similar techniques, Kloda and Czajkowski (2007) probed loop E of the vertebrate 
GABAA receptor subunit α1, also looking for residues that potentially line the agonist 
binding pocket.  In both studies, pocket lining residues were found in loop E (GABAA α1: 
N115C, L117C, T129C, and R131C; GABAc ρ1: V155C, M156C, V159C, S168C, and 
R170C). While some of the binding pocket residues found in GABAC were also found in 
GABAA, there were some residues that were different.  It is possible that these unique 
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residues may explain (at least in part) the differences observed in the pharmacology and 
receptor kinetics between the two classes of vertebrate GABA receptors. 
Due to the similarity in architecture of all ionotropic GABA receptors within the 
Cys-loop family, it can be assumed that important binding site residues are located in loop 
E of Hco-UNC-49 as well.  However, similar to GABAC, there may be unique residues 
responsible for GABA activation in Hco-UNC-49. This discovery would advance our 
understanding of GABA receptors, and the possible causes for the pharmacological variety 
observed in the GABA LGCC family.  
Specifically, the thesis herein will focus on outlining which of the 18 residues 
within loop E are important for GABA-activation of Hco-UNC-49, and which residues are 
in aqueous environments, potentially lining the GABA binding pocket.  Furthermore, the 
thesis will describe the uniqueness of the important residues, and how loop E of Hco-UNC-
49 compares to its vertebrate counterparts.   
Therefore, the objective of this thesis is to use SCAM analysis to probe the residues 
in binding loop E to determine which are important for the function of the Hco-UNC-49 


































2.1 Site-Directed Mutagenesis – Primer Design 
 Amino acid alignments of Hco-unc-49b (Genbank Accession # EU939734.1) and 
other GABA receptor subunits in the ligand-gated chloride channel (LGCC) family 
(GABAC rho-1, GABAA alpha-1, Cel-UNC-49B, AChBP, etc.), were used to determine 
the location of loop E within the H. contortus sequence (Hco-UNC-49B, GABAA, and 
GABAC alignment shown in Figure 5). Located between the  histidine residue at position 
142 and the leucine residue at 160, primers were designed using Stratagene’s web-based 
QuikChange® Primer Design program (www.stratagene.com/sdmdesigner/default.aspx) 
to create 18 mutants (H142C, N143C, S144C, F145C, L146C, R147C, I148C, D149C, 
S150C, D151C, G152C, T153C, V154C, Y155C, T156C, S157C, Q158C, and R159C). 
Each pair of mutagenic primers (Table 1) were designed to change amino acid residues 
along loop E into cysteine residues, by way of nucleotide introduction, resulting in singly 




Figure 5. Amino Acid Alignment of Loop E in GABA Receptor Subunits Hco-UNC-49B, GABAA α1, and 
GABAc ρ1. Hco-UNC-49B is from Haemonchus contortus and shows residues from His142-Leu160.  GABAA 
α1 is obtained from a rat and demonstrates residues Met113-Leu132.  GABAC ρ1 amino acid sequence is human, 




Table 1. Hco-UNC49B Cysteine Mutagenesis Primers.  Each mutagenesis primer name indicates the residue to be mutated, the position of the residue in the Hco-
UNC-49B amino acid sequence, and the new residue in the mutant (which is cysteine for all).  Mutagenesis primers were designed using Stratagene’s web-based 








H142C 5'-tttccacttggccacaacgtgtaactctttcctgcgaatc-3 5'-gattcgcaggaaagagttacacgttgtggccaagtggaaa-3' 
N143C 5'-cacttggccacaacgcattgctctttcctgcgaatcg-3' 5'-cgattcgcaggaaagagcaatgcgttgtggccaagtg-3' 
S144C 5'-ggccacaacgcataactgtttcctgcgaatcgac-3' 5'-gtcgattcgcaggaaacagttatgcgttgtggcc-3' 
F145C 5'-ccacaacgcataactcttgcctgcgaatcgacag-3' 5'-ctgtcgattcgcaggcaagagttatgcgttgtgg-3' 
L146C 5'-ccacaacgcataactctttctgccgaatcgacagcgatggcac-3' 5'-gtgccatcgctgtcgattcggcagaaagagttatgcgttgtgg-3' 
R147C 5'-cgcataactctttcctgtgcatcgacagcgatggcac-3' 5'-gtgccatcgctgtcgatgcacaggaaagagttatgcg-3' 
I148C 5'-cataactctttcctgcgatgcgacagcgatggcacg-3' 5'-cgtgccatcgctgtcgcatcgcaggaaagagttatg-3' 
D149C 5'-ctctttcctgcgaatctgcagcgatggcacggtc-3' 5'-gaccgtgccatcgctgcagattcgcaggaaagag-3' 
S150C 5'-cctgcgaatcgactgcgatggcacggt-3' 5'-accgtgccatcgcagtcgattcgcagg-3' 
D151C 5'-cctgcgaatcgacagctgtggcacggtctacact-3' 5'-agtgtagaccgtgccacagctgtcgattcgcagg-3' 
G152C 5'-gcgaatcgacagcgattgcacggtctacact-3' 5'-agtgtagaccgtgcaatcgctgtcgattcgc-3' 
T153C 5'-cgaatcgacagcgatggctgcgtctacactagtcaacgg-3' 5'-ccgttgactagtgtagacgcagccatcgctgtcgattcg-3’ 
V154C 5'-cgacagcgatggcacgtgctacactagtcaacgg-3' 5'-ccgttgactagtgtagcacgtgccatcgctgtcg-3' 
Y155C 5'-cgatggcacggtctgcactagtcaacggc-3' 5'-gccgttgactagtgcagaccgtgccatcg-3' 
T156C 5'-cgatggcacggtctactgtagtcaacggcttacg-3' 5'-cgtaagccgttgactacagtagaccgtgccatcg-3' 
S157C 5'-ggcacggtctacacttgtcaacggcttacgg-3' 5'-ccgtaagccgttgacaagtgtagaccgtgcc-3' 
Q158C 5'-gcgatggcacggtctacactagttgccggcttacggtc-3' 5'-gaccgtaagccggcaactagtgtagaccgtgccatcgc-3' 




2.2 Site-Directed Mutagenesis of Hco-unc-49b 
 The template used in the site-directed mutagenesis of Hco-UNC-49B was 
previously sub-cloned into a pT7Ts transcription vector, in which Xenopus laevis β-globin 
untranslated DNA was incorporated into the 5’ and 3’ ends of the Hco-UNC-49B cDNA 
(Siddiqui et al., 2010).  
A naturally occurring cysteine residue was located at position 224 of the template 
amino acid sequence, and was removed through site-directed mutagenesis to prevent 
interference with results obtained from the inserted cysteine residues present in the Hco-
UNC-49B mutants. With no alteration in function (Figure 6; Table 2), the cysteine-less 
mutant (C224A) was used as template, and a baseline from which all data obtained could 
be compared to throughout the project.   
All site-directed mutagenesis performed was conducted using the QuikChange ® 
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the 
manufacturer’s instructions. Confirmation that the correct mutation was present was 
verified using DNA sequencing (Genome Quebec).   
 
2.3 cRNA Preparation – In Vitro Transcription 
 Plasmid constructs containing either the mutated Hco-unc-49b or wild-type (WT) 
Hco-unc-49c (Genbank Accession # EU049602.1) were linearized and used as template 
(0.4-1 µg) to create capped Hco-unc-49 copy RNA (cRNA). The cRNA was made using 
the mMessage mMachine in vitro transcription reaction and the T7 RNA polymerase 
provided within the transcription kit (Ambion, Austin, TX, USA). cRNA made was 
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subjected to deoxyribonuclease, precipitated using lithium chloride, and brought to a 
concentration of 0.5 ng/L upon re-suspension in nuclease free water.  Each in vitro 
transcription reaction yielded approximately 10-25 µg of cRNA.  
 
2.4 Expression of Hco-UNC49BC in Xenopus laevis Oocytes 
 Oocytes were obtained surgically from female X. laevis (kept in temperature 
controlled rooms at UOIT; originally received from Nasco, Fort Atkinson, WI, USA), 
anaesthetized with 0.15% 3-aminobenzoic acid ethyl ester methane sulphonate salt (MS-
222; Sigma-Aldrich, Oakville, ON, CA). Lobes of the ovary were extracted, split into 
smaller pieces of 10-20 oocytes, and defolliculated in a treatment of 2 mg/mL collagenase-
II (Sigma-Aldrich) and OR2 solution (82 mM NaCl, 2m M KCl, 1m M MgCl2, 5 mM 
HEPES pH 7.5) for two hours with gentle rocking at room temperature. After 
defolliculation, oocytes were stored at 20ºC in ND96 buffer (96 mM NaCl, 2 mM KCl, 1.8 
mM CaCl2, 1 mM MgCl2, 5 mM HEPES pH 7.5) supplemented with 100 µg/mL 
gentamycin and 0.275 µg/mL pyruvic acid (Sigma-Aldrich). Supplemented ND96 
solutions were replaced twice every 24 hour period. To reduce the number of operations 
performed on X. laevis, excess ovarian lobes from surgeries were incubated at 4ºC in 
supplemented ND96 buffer that was replaced once every 24 hours (replacement ND96 
chilled to 4ºC). Lobes were prepared and defolliculated after one week of storage as 
described previously.  
 Cytoplasmic injections of cRNA were carried out on stage V and VI oocytes using 
a Drummond Nanoject II (Drummond Scientific Company, Broomhall, PA, USA) assisted 
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by micromanipulators (World Precision Instruments, Inc., Sarasota, FL, USA). Each 
oocyte was injected with 50 nL of a mixture of mutated Hco-unc-49b and WT Hco-unc-
49c (equal amounts of 0.5 ng/nL cRNA of each). Electrophysiological recordings were 
taken after receptor expression, approximately 2-5 days after cRNA injection.  
 
2.5 Two-Electrode Voltage Clamp (TEVC) Electrophysiology 
 Using an Axoclamp900A voltage clamp (Molecular Devices, Sunnyvale, CA, 
USA), TEVC electrophysiology was used to observe and record channel activity of Hco-
UNC-49BC. Glass electrodes were pulled from borosilicate capillaries using a P-97 
Flaming/Brown micropipette puller (Sutter Instruments Company, Novato, CA, USA), and 
filled with 3M KCl (1-5 MΩ resistance). Each of the two electrodes were connected to 
Axon Instrument Headstages (Molecular Devices) using Ag|AgCl wires. Oocytes were 
pierced on either side with the glass electrodes, in which one electrode clamped the 
oocyte’s voltage at -60mV, while the other measured changes to the current caused by 
activation of the receptor and subsequent channel opening. Compounds used for various 
analyses utilizing TEVC electrophysiology were perfused over the oocytes through a 
gravitational flow system into an RC-1Z perfusion chamber (Warner Instruments Inc, 
Holliston, MA, USA). ND96 buffer was used to dilute the various compounds used, in 
addition to being used as a wash solution in between drug applications. Recordings and 
associated data were obtained using Axon Instruments Digidata 1440, Clampex 10.2, and 
analyzed via Clampfit 10.2 (Molecular Devices).  
25 
 
 EC50s were determined for each mutant by perfusing increasing concentrations of 
GABA (or other agonists) and recording the current observed which included the 
concentration of agonist that produced maximal current.  
 
2.6 Substituted Cysteine Accessibility Method (SCAM) 
 Cysteine Accessibility was determined for 10 Hco-UNC-49B mutants (H142C, 
N143C, S144C, F145C, L146C, R147C, I148C, D149C, S150C, and S157C) as well as the 
cysteine-less mutant (C224A) using two separate methanethiosulfonate (MTS) reagents.  
The two MTS reagents used in this project were 2-hydroxyehtylthiosulfonate (MTSET) 
and 2-aminoethylmethanethiosulfonate (MTSEA), and were obtained from Toronto 
Research Chemicals (Toronto, ON, CA). During testing, an oocyte was washed and hit 
with EC20-50 concentrations of GABA in 5 minute intervals until response stabilized within 
10%. Once stabilized, either MTSET or MTSEA (1mM for 1 min) was perfused over the 
oocyte, followed by 5 min of wash with ND96 solution (composition described elsewhere). 
The EC20-50 concentrations of the mutant being tested was re-applied, and currents were 
recorded (Sedelnikova et al., 2004, and Kloda & Czajkowski, 2006).  
 Protection assays were conducted on Hco-UNC-49B mutant H142C and S157C 
using approximately 100 times the EC50 established for the receptor during co-application 
of GABA (270 µM and 35 mM respectively) and MTSET. The EC50 of GABA was used 
to stabilize the response, and to determine if protection occurred. Standard procedures 
involved exposing the oocyte to GABA every 5 minutes until current stabilized within 10% 
of each response, saturated amounts of GABA with MTSET (1 mM MTSET + 100x EC50 
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GABA for 1 min) were then applied, oocyte was washed for 5 minutes, EC50 GABA was 
re-applied, oocyte was washed for 3 minutes, MTSET (1 mM, 1 min) was applied alone, 
and GABA EC50 was applied again to determine effect.  
  
2.7 Statistical Analysis 
 Dose-response curves were generated by Prism 5.0 (Graphpad Software, San 






Where Imax is the maximal response, [D] is the concentration of agonist, EC50 is the 
concentration of agonist that is required to produce half-maximal current, and h is the Hill 
coefficient. Responses used to produce dose-response curves were normalized as a 
percentage of the maximal current produced by the oocytes individual maximal response 
to GABA. 
 The effect of MTS modification was calculated using the following formula: 
  − 1 
Where IGABA-post is the current produced from GABA activation of the receptor after the 
application of MTS reagent, and IGABA-pre is the current produced from GABA activation 
before the MTS reagent was applied (Kloda & Czajkowski, 2006).    
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EC50 values, h values, and standard error (S.E.) were determined using Prism 5.0 
from a minimum of three oocytes from two different X. laevis. Bar graphs displaying fold 
changes, comparative currents, and SCAM results were produced from Microsoft Excel 
2010.  Statistical significance was derived from student t-tests using SigmaPlot 12.5 

































3.1 Characterization of Loop E Cysteine Mutants in Hco-UNC-49BC 
 The first stage in determining the importance of amino acids residues in loop E of 
Hco-UNC-49B, to the activation of Hco-UNC-49BC, was to assess their impact on GABA-
activation of the channel. Through the use of TEVC electrophysiology, each loop E mutant 
was exposed to increasing concentrations of GABA for the purpose of determining EC50 
values. Upon recording, good expressions of all receptors with mutated subunits were 
observed, all receptors were functional, and clean tracings were obtained (Figure 6A).  
 Of the 18 mutants tested, 15 showed a significant shift in GABA EC50 compared to 
the C224A cysteine-less mutant from which they were derived (representative dose-
response curves are seen in Figure 6B). Of the mutants that displayed a different EC50 from 
C224A (32.56 µM ± 2.29), both H142C and I148C showed an unexpected increase in 
GABA sensitivity (2.70 µM ± 0.22 and 19.37 µM ± 2.62 respectively). The remaining 13 
mutants (N143C, S144C, F145C, L146C, R147C, S150C, G152C, T153C, V154C, Y155C, 
T156C, S157C, and R159C) had a decrease in GABA sensitivity, with S157C and R159C 
showing the greatest increase in EC50 values (3683.50 µM ± 413.66 and 3102.33 µM ± 
130.43 respectively). Finally, three of the cysteine mutants, D149C, D151C, and Q158C, 
showed no statistical change in GABA EC50 (P<0.05).  
For ease of comparison, the fold change EC50 values compared to the EC50 of 
C224A were determined (Figure 7), and all EC50 values (±S.E.) with Hill coefficients were 
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Figure 6. A) Representative electrophysiological tracings of Hco-UNC-49BC with mutated Hco-UNC-49B 
subunits H142C, C224A (cysteine-less mutant used as template for creation of other mutants), and S157C. 
B) Dose-response curve of Hco-UNC-49B mutants showing large changes in GABA sensitivity, with 




















Figure 7. Fold change of EC50, normalized to C224A mutant of Hco-UNC-49B (cysteine-less mutant with 
WT responses, used as template for creation of other Loop E mutants). Each bar represents a mean of fold 
change ± S.E. Black bars show statistical significance (P<0.05), and gray bars denote no statistical 
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Table 2. Comparison of EC50 and Hill slope values of Hco-UNC-49B mutants assembled as heteromeric 
Hco-UNC-49BC receptors, with GABA.  
 
MUTATION EC50 ± S.E. (µM) 
(HILL COEFFICIENT ± S.E.) 
NUMBER OF 
OOCYTES 
C224A 32.56 ± 2.29 
(1.37 ± 0.11) 
7 
H142C 2.70 ± 0.22 
(1.44 ± 0.07) 
7 
N143C 199.69 ± 22.86 
(1.33 ± 0.11) 
7 
S144C 133.76 ± 11.96 
(1.31 ± 0.07) 
7 
F145C 383.53 ± 114.30 
(1.40 ± 0.04) 
7 
L146C 361.39 ± 42.59 
(1.30 ± 0.04) 
7 
R147C 90.32 ± 6.54 
(1.82 ± 0.16) 
8 
I148C 19.37 ± 2.62 
(1.53 ± 0.13) 
8 
D149C 39.79 ± 7.11 
(2.15 ± 0.27) 
7 
S150C 54.39 ± 6.95 
(1.78 ± 0.13) 
7 
D151C 36.11 ± 3.25 
(1.43 ± 0.08) 
7 
G152C 54.91 ± 5.01 
(1.48 ± 0.06) 
7 
T153C 122.21 ± 10.01 
(1.71 ± 0.08) 
6 
V154C 104.05 ± 5.10 
(1.51 ± 0.14) 
7 
Y155C 111.49 ± 10.68 
(1.64 ± 0.09) 
7 
T156C 628.48 ± 50.61 
(1.71 ± 0.06) 
6 
S157C 3683.50 ± 413.66 
(1.43 ± 0.09) 
8 
Q158C 35.44 ± 6.63 
(1.44 ± 0.10) 
7 
R159C 3102.33 ± 130.43 




3.2 Determination of Cysteine Accessibility    
 Substituted cysteine accessibility method (SCAM) was performed on 
approximately half of the loop E Hco-UNC-49B mutants made (C224A, H142C, N143C, 
S144C, F145C, L146C, R147C, I148C, D149C, S150C, and S157C). It was found that out 
of the 11 mutants tested, only H142C, S144C, R147C, and S157C were modified using 
MTSET (Figure 8). Furthermore, only S157C had a decrease in % Change in IGABA (-
49.75% ± 7.83). Conversely, H142C, S144C, and R147C all showed an increase in % 






















Figure 8. Impact of MTSET on current evoked from GABA activation (IGABA) of Hco-UNC-49BC receptors 
with mutated Hco-UNC49-B subunits. A) Representative tracings of current elicited from GABA (EC20) 
before and after MTSET application (1 mM, 1 min). B) Percentage change in current from treatment of 
mutant Hco-UNC-49BC receptors with MTSET. Each bar indicates the mean ± S.E. (n>3). Black bars 
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In addition to MTSET, cysteine accessibility tests were performed with MTSEA 
(Figure 9). Similar trends in % Change in IGABA were observed for S157C, H142C, S144C, 
and R147C (-73.14% ± 7.14, 76.98% ± 18.20, 34.20% ± 8.92, and 50.30% ± 4.48). 
However, increased instability of the X. laevis oocytes and unexplained reactivity (most 
likely due to oocyte quality) with the cysteine-less mutant C224A (% Change IGABA = 




Figure 9. Impact of MTSEA on current evoked from GABA activation (IGABA) of Hco-UNC-49BC receptors 
with mutated Hco-UNC49-B subunits. Percentage change in current from treatment of mutant Hco-UNC-





3.3 Effect of Agonist Binding on Cysteine Modification  
 Hco-UNC-49B mutants H142C and S157C were analyzed via GABA protection 
assays. It was determined that H142C was protected to a statistically significant degree 
(approximately 16.25% difference between MTSET + GABA application and MTSET 
application alone; P<0.05) by GABA (Figure 10). On the other hand, S157C was protected 
to a small degree (approximately 4.5% difference), but this difference was not found to be 






























Figure 10. Effects of GABA on MTSET modification of Hco-UNC-49BC Loop E cysteine mutants. A) 
Representative tracings of currents elicited by EC50 GABA on Hco-UNC-49BC (B subunit mutants H142C 
and S157C), in which arrows represent the application of either MTSET + GABA (100x EC50 GABA) or 
MTSET alone, applied in between EC50 GABA hits. B) % Change of IGABA displaying the modification of 
H142C and S157C with MTSET (black bar) and MTSET + GABA (gray bar).  Each bar represents the mean 
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3.4 Further Characterization of H142C Mutant 
 Upon discovering hypersensitivity to GABA in H142C two other agonists were 
analyzed, 5-aminovaleric acid (DAVA) and imidazole-4-acetic acid (IMA).  EC50 values 
(± S.E.) were determined for both compounds (Table 3) from generated dose-response 
curves (Figure 11B). From recorded currents, it was determined that both DAVA and IMA 
act as full agonists on this mutant receptor (Figure 11A), creating maximal currents that 
were as large as those elicited by maximal GABA concentrations. Finally, by comparing 
DAVA and IMA EC50 values for H142C to Hco-UNC-49BC wild-type, it was found that 




Table 3. Comparison of EC50 and Hill slope values of Hco-UNC-49B mutant H142C (assembled as 





EC50 ± S.E. (µM) 




EC50 ± S.E. (µM) 
(Hill Coefficient ± S.E.) 
 
n 
IMA 65.47 ± 6.26 
(1.34 ± 0.13) 
6 174.53 ± 20.75 
(1.93 ± 0.17) 
11 
DAVA 1353.2 ± 246.2 
(1.15 ± 0.16) 
7 3914 ± 520 
(1.47 ± 0.18) 
7 
GABA 2.70 ± 0.22 
(1.44 ± 0.07) 
7 59.24 ± 7.73 
(2.5 ± 0.42) 
9 























Figure 11. IMA and DAVA are full agonists for Hco-UNC-49BC H142C mutant. A) Electrophysiology 
tracings representing maximum response to IMA and DAVA compared to maximal GABA response. B) 
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This thesis was concerned with characterizing binding loop E in Hco-UNC-49, a 
GABA-gated chloride channel belonging to the Cys-loop family of receptors. Loop E 
residues have been shown to line the agonist binding pocket of both GABAA (Kloda & 
Czajkowski, 2006) and GABAC (Sedelnikova et al., 2005) vertebrate receptors, and due to 
the similarity in structure shared by all receptors in the Cys-loop LGCC family, it stands 
to reason that residues in loop E of Hco-UNC-49 may also have this role. In order to 
determine if this was true, residues in loop E were mutated and analyzed for functional 
effects. Due to time constraints, approximately half of the analyzed mutants were tested to 
determine if they were in an aqueous environment, and two of these mutants underwent 
further experimentation to determine if the aqueous environment resides in the binding 
pocket. Finally, H142C, a hypersensitive mutant, was exposed to additional compounds to 
further elucidate its role in the function of Hco-UNC-49.  
 
4.1 Hco-UNC-49B Loop E Mutants Effect Functionality of Hco-UNC-49BC  
 The first objective of this thesis was to determine if residues within loop E of Hco-
UNC-49BC are important to the function of the receptor. As stated elsewhere, only 3 
mutants (D149C, D151C, and Q158C) did not impact the functionality of the receptor, 
exhibiting EC50 values close to those obtained from C224A (the baseline). From these 
results, it is believed that the aspartic acid at position 149 and 151, as well as the glutamine 
at position 158, are not essential for Hco-UNC-49 to function.  
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 The remaining loop E mutants tested, showed a significant difference in their EC50 
values compared to C224A. Out of all of the mutants analyzed, H142C, S144C, R147C, 
T153C, S157C, and R159C, produced interesting results.  
Within Hco-UNC-49BC, the results seem to suggest that serine at 144 and 
threonine at 153 are both significant for the receptor to function normally. This was 
evidenced by the fold change in the EC50 values of S144C and T153C compared to the 
baseline C224A mutant (4.1 ± 0.38 and 3.7 ± 0.31 fold increase respectively). While the 
fold change may not appear large, the difference was statistically significant (P<0.05). This 
finding is interesting because there was no effect observed when mutating the orthologous 
amino acid residues at the same positions, in either the GABAA α1 subunit or the GABAC 
ρ1 subunit (Sedelnikova et al., 2005; Kloda & Czajkowski, 2006). The serine at position 
144 in Hco-UNC-49B aligns to a lysine in the GABAA α1 subunit (position 157) and a 
valine in the GABAC ρ1 subunit (position 155). Since these three amino acids contain very 
different properties and overall structures (i.e. polar, positively charged, and nonpolar 
residues), it is reasonable to believe that they play different roles in receptor activation.  
However, the threonine at position 153 in Hco-UNC-49B is a conserved residue found at 
the equivalent position in the GABAA α1 subunit (position 121). Regardless of this 
conservation, the cysteine mutant T121C did not alter the EC50 of the GABAA receptor, 
suggesting a different role for an equivalent residue in the vertebrate and invertebrate 
GABA receptor. 
Although some amino acid residues held importance to the function of Hco-UNC-
49BC, and were not essential in GABAA or GABAC receptors, the opposite was also true. 
When an arginine residue at position 147 of the Hco-UNC-49B amino acid sequence was 
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mutated to a cysteine, there was a 2.7 ± 0.20 fold increase observed in the EC50 of Hco-
UNC-49BC. Again, this difference did not appear large, but was statistically significant 
(P<0.05). When Hco-UNC-49B was aligned with the GABAA α1 subunit and the GABAC 
ρ1 subunit, it was found that this arginine residue is conserved at the same position across 
all receptors (position 119 in GABAA and 158 in GABAC). When this arginine residue was 
mutated to a cysteine in the GABAA α1 subunit, there was a fold change of 260.5 when 
comparing the mutant EC50 to that of the wild-type (Kloda & Czajkowski, 2006). 
Sedelnikova et al. (2005) mutated this arginine to a cysteine in the GABAC ρ1 subunit, and 
reported that the mutant receptor was expressed to such a low degree that further analyses 
could not be conducted. This lack of expression could indicate that the residue in question 
is required for assembly or structural integrity, and that the mutation is not tolerated in the 
protein (Newell & Czajkowski, 2003). It stands to reason that this specific arginine holds 
significant importance to the conductance and functionality of vertebrate ionotropic GABA 
receptors. However, this was not the case for Hco-UNC-49BC. Although the residue is 
conserved, it appears to hold a less significant role in the invertebrate receptor, for reasons 
that are still unclear.  
Another unique residue in loop E of Hco-UNC-49B was uncovered through 
mutational analysis. A histidine residue at position 142 sits at the very beginning of loop E 
in the Hco-UNC-49B subunit in H. contortus. The equivalent amino acid in this position 
in the GABAA α1 subunit is a proline (at position 114). Upon mutation to a cysteine residue, 
Kloda & Czajkowski (2007) reported an increase in GABA EC50 when compared to the 
wild-type (5.4 fold change). While not unremarkable, this result differs heavily from what 
was uncovered in Hco-UNC-49. When the histidine was mutated to a cysteine in Hco-
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UNC-49B, the EC50 of H142C dropped significantly from 32.56 µM GABA (± 2.29) to 
2.70 µM (± 0.22). With a fold change of over 1/10 (approximately 0.08), this mutation 
created a hypersensitive receptor. In other studies conducting SCAM on binding loop 
residues of various GABA receptors, there have been no reports of extreme increases to 
GABA sensitivity after the mutation of the residue to a cysteine, and moderate increases 
observed are not accompanied by explanation (Boileau et al., 1999, 2002; Newell & 
Czajkowski, 2003; Sedelnikova et al., 2005; Kloda & Czajkowski, 2006). In regards to 
Hco-UNC-49B, since histidine is an amino acid with a bulky side group, it is possible that 
removal of it opens up the binding pocket, reducing specificity and increasing sensitivity. 
In this sense, His142 could be responsible for limiting the function of Hco-UNC-49, thereby 
controlling the degree to which the GABA receptor can be activated by its agonist. Further 
studies would allow for a clearer picture of the restrictions produced by His142, and 
mutation of this residue to other amino acids would have to be done for full 
characterization.  
  Finally, while a few unique residues were found in Hco-UNC-49B loop E, there 
were some results that adhered to the findings in the GABAA and GABAC receptors. Most 
notably, Ser157 and Arg159 showed massive changes to their EC50 values when mutated to 
a cysteine residue (fold change of 113.1 and 96.27 respectively). The arginine residue at 
position 159 appears to be conserved across Hco-UNC-49B, the GABAA α1 subunit 
(Arg131), and the GABAC ρ1 subunit (Arg
170). In all cases, removal of the arginine residue 
led to a decrease in GABA sensitivity, with fold changes ranging from 10 to 67.4. These 
results suggest that the arginine at this position possibly serves similar roles in activation. 
The same can be said for Ser157. It is relatively conserved across Hco-UNC-49BC, with the 
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GABAA α1 subunit exhibiting the chemically similar Thr
129, and the GABAC ρ1 subunit 
exhibiting a serine at positon 168. When the residue was removed from this position, and 
replaced by a cysteine, large changes in EC50s were observed (fold change S157C = 113.1, 
S168C = 400, T129C = 102). Once again, this suggests that equivalent amino acids play a 
similar role in the activation of different GABA receptors.  
 
4.2 Loop E Residues Are Found Within Aqueous Environments 
 Approximately half of the loop E Hco-UNC-49B mutants were analyzed using 
SCAM to determine if the residue lies within an aqueous environment. Of the mutants 
tested, only H142C, S144C, R147C, and S157C showed any significant change in IGABA 
after the application of MTSET (also showed a significant change with MTSEA). From 
this, it concluded that His142, Ser144, Arg147, and Ser157 are likely found in hydrophilic 
environments either in the binding pocket or elsewhere.  
 Although four of the mutants tested exhibited a change in the IGABA, only S157C 
showed a decrease. This decrease is consistent with modification of a sulfhydryl group 
located within the binding pocket, as the MTS modification would inhibit the binding of 
GABA, and overall receptor activation (Newell & Czajkowski, 2007). In this sense it is 
likely that Ser157 is in the binding pocket of Hco-UNC-49BC, but the residue could just as 
easily be otherwise situated in a position effected by allosteric modulation. The other three 
mutants shown to be sensitive to MTS modification (H142C, S144C, and R147C) 
displayed an increase in IGABA, suggesting a potentiation of the GABA current response. In 
a study aimed at mapping the agonist binding site of the GABAA receptor, Boileau et al. 
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(1999) also reported finding a cysteine mutant in the loop D α-subunit that appeared to 
have an increase in current potentiation after modification with MTSEA. The cause for an 
increase in response, rather than the expected decrease, is believed to be a result of an 
indirect effect of modification, perhaps leading to enhanced gating and overall increase in 
GABA affinity (Boileau et al., 1999). Although this is a likely reason for the results 
observed in H142C, S144C, and R147C mutants of Hco-UNC-49B, the high degree to 
which the response increased in H142C (over 90%),  paired with its hypersensitivity, makes 
His142 an interesting residue that requires further experimentation and attention.    
 Further comparison of our results with the GABAA and GABAC receptors (Kloda 
& Czajkowski, 2007; Sedelnikova et al., 2005) revealed some interesting trends. Ser157 in 
Hco-UNC-49 was found to be in an aqueous environment, and the analogous residue was 
also found to line the binding pocket in the GABAA α1 subunit (Thr
129) and the GABAC 
ρ1 subunit (Ser168). The same trend was also found for Ser144 in Hco-UNC-49 and the 
GABAC ρ1 subunit (Val
155). However the location of His142 in an aqueous environment 
appears to be unique to Hco-UNC-49BC. In addition, Asn115 of the GABAA α1 subunit and 
Val159 of the GABAC ρ1 subunit seem to be pocket lining residues (Kloda & Czajkowski, 
2006; Sedelnikova et al., 2005), but the equivalent residues in the Hco-UNC-49B protein 
(Asn143 and Ile148) are not.  How these unique differences relate to differences in the 






4.3 Agonist protection of H142C from MTS Modification 
 Out of the four mutants determined to be sensitive to modification with MTSET, 
and subsequently represent those residues located in an aqueous environment, H142C and 
S157C underwent analysis via the protection assay. Due to the large change in IGABA 
observed when Ser157 was replaced with a cysteine residue, and because equivalently 
located Ser168 and Thr129 in GABAC and GABAA receptor subunits were shown to be lining 
the binding pocket (Sedelnikova et al., 2005; Kloda & Czajkowski, 2006), it was predicted 
that excess amounts of GABA would protect S157C from MTS modification. However, 
this was not the case. While a small amount of protection was conferred from the agonist, 
this was determined to not be statistically significant. The cause of this result could be due 
to a couple of reasons. First, it could be that Ser157 is not lining the binding pocket, and lies 
in an aqueous environment within another region of the protein. In this sense, Ser157 could 
have an indirect effect on the GABA activation of Hco-UNC-49BC. Regardless, the 
removal of Ser157 severely hampers the normal function of the receptor, and effect 
exacerbated when the sulfhydryl group of S157C is irreversibly modified by MTSET. The 
second explanation could lie in the MTS reagent itself. It is possible that Cys157 of S157C 
is in a position where MTSET binds to and sterically hinders the binding of GABA, but 
that GABA is somehow too small to protect the residue from modification (Boileau et al., 
1999).  
 Since the H142C mutant of Hco-UNC-49B was a hypersensitive mutant, and 
modification of the cysteine potentiated the GABA current response, it was predicted that 
His142 would not be in the binding pocket, and therefore remain unprotected when GABA 
was co-applied with MTSET. Once again, this was not the case. It was determined that 
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GABA protected the cysteine of H142C from modification to a small, but significant 
degree. Interestingly, the protection conferred by GABA was protection from potentiation 
of the current response. In other words, the current elicited by the agonist was larger when 
MTSET was applied alone, than when GABA and MTSET were co-applied. A possible 
explanation is that His142 resides in an aqueous environment outside of the binding pocket, 
but moves as a result of allosteric modulation of the protein when GABA binds, becoming 
less exposed to MTSET. Further study is required to elucidate whether this is the case. A 
protection assay using a competitive antagonist may reveal if the results observed are due 
to conformational changes. 
  
4.4 Mutation at H142C Changes Functionality of Hco-UNC-49BC 
 Throughout the thesis, H142C has produced some unexpected and interesting 
results. To further characterize this mutant, in the hopes of understanding the role His142 
plays in the function of Hco-UNC-49BC, DAVA and IMA were applied and EC50 values 
determined. Hypersensitive to both DAVA and IMA compared to the wild-type 
(experiments of wild-type performed by Mark Kaji, 2012), H142C continues to show 
increased affinity for agonists, strengthening the argument that His142 effects the binding 
site in Hco-UNC-49. Furthermore, it was found that both of these compounds elicit a 
current equal to the maximal response created by GABA. A recent paper from our lab (Kaji 
et al., 2014, submitted) found that DAVA is a partial agonist to the H. contortus GABA 
receptor and only produces 30% of the maximal GABA current. However, when His142 
was removed and replaced with a cysteine residue, DAVA achieved maximal conductance, 
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and presented as a full agonist. This finding further supports the idea that His142 in binding 
loop E may have a negative effect on the binding of agonists such as GABA and DAVA. 
 
4.5 Conclusion 
 The objective of this thesis was to further characterize Hco-UNC-49BC, the 
GABA-gated chloride channel found within H. contortus. This objective was met by 
analyzing the amino acid residues in binding loop E, specifically looking for those that 
interact either directly or indirectly with the GABA activation of the channel. It was found 
that of the loop E mutants analyzed, His142, Ser144, Arg147, and Ser157 are found in aqueous 
regions of the protein. Furthermore, it was determined that His142 and Ser157 probably 
interact indirectly, although more research is required to confirm this finding. Finally, as a 
result of this thesis, His142 was identified as a residue that has a major role in the sensitivity 
and selectively of Hco-UNC-49. When replaced, mutants lacking His142 showed increased 
sensitivity to agonists (GABA, DAVA, and IMA) which produced maximal chloride 
conductance not observed in the wild-type form of the receptor (DAVA).  
 While more work is required to fully characterize Hco-UNC-49BC, the work from 
this thesis suggests that Hco-UNC-49BC shows promise as a future drug target. The 
receptor, already known to have a unique pharmacology, is beginning to reveal what 
structural differences may account for the difference observed functionally. In addition, by 
uncovering residues in Hco-UNC-49B that appear to have a role in the function of the 
invertebrate receptor, while showing little significance to the function of vertebrate GABA 
receptors, we can begin to tease apart the differences between the two. With future studies 
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on loop E (completed tests of cysteine accessibility and protection assays) and other 
binding loops of various nematode receptors, the knowledge within the field of GABA 
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Hco-UNC-49B                  142  H N S F L R I D S D G T V Y T S Q R 159 
H142C                               142  C N S F L R I D S D G T V Y T S Q R 159 
N143C                               142  H C S F L R I D S D G T V Y T S Q R 159 
S144C                                142 H N C F L R I D S D G T V Y T S Q R 159 
F145C                                142 H N S C L R I D S D G T V Y T S Q R 159 
L146C                               142  H N S F C R I D S D G T V Y T S Q R 159 
R147C                               142  H N S F L C I D S D G T V Y T S Q R 159 
I148C                                142  H N S F L R C D S D G T V Y T S Q R 159 
D149C                               142  H N S F L R I C S D G T V Y T S Q R 159 
S150C                                142 H N S F L R I D C D G T V Y T S Q R 159 
D151C                               142  H N S F L R I D S C G T V Y T S Q R 159 
G152C                               142  H N S F L R I D S D C T V Y T S Q R 159 
T153C                               142  H N S F L R I D S D G C V Y T S Q R 159 
V154C                               142  H N S F L R I D S D G T C Y T S Q R 159 
Y155C                               142  H N S F L R I D S D G T V C T S Q R 159 
T156C                               142  H N S F L R I D S D G T V Y C S Q R 159 
S157C                                142 H N S F L R I D S D G T V Y T C Q R 159 
Q158C                               142  H N S F L R I D S D G T V Y T S C R 159 
R159C                               142  H N S F L R I D S D G T V Y T S Q C 159 
 
 
Amino Acid sequences of Loop E in Hco-UNC-49B and single-cysteine mutants. The mutation in each 
cysteine mutant is represented by a C, indicating the substitution of an amino acid to cysteine.  
 
